

MODERN SLAVERY AND HUMAN TRAFFICKING STATEMENT

Financial Year ended 31 December 2025

Published pursuant to Section 54 of the Modern Slavery Act 2015

Effective Date: 2026-05-21

1. Introduction

This statement is made pursuant to Section 54(1) of the Modern Slavery Act 2015 and constitutes Surgical Science's slavery and human trafficking statement for the financial year ending 31 December 2025.

This is Surgical Science's first Modern Slavery Statement. It reflects a foundation year, during which we focused on establishing policies, governance, and initial risk awareness.

We recognise that this is the beginning of an ongoing process. We are committed to building on this foundation year on year, strengthening our approach as our understanding of the risks develops and our practices mature.

2. Our Organisation and Supply Chains

2.1 About Surgical Science

Surgical Science is a global medical simulation company specialising in the development and sale of virtual reality simulation solutions for medical training. Our purpose is to provide medical professionals with the opportunity to train before entering the clinical environment, improving patient care and ultimately saving lives.

Surgical Science is headquartered in Gothenburg, Sweden, and is listed on the Nasdaq First North Growth Market in Stockholm. We operate across multiple countries, with employees and commercial activities in Europe (including Sweden and the United Kingdom), North America, and Israel.

2.2 Our Supply Chains

Our supply chains consist of electronic components and hardware for our simulation platforms, software development services, professional and IT services, logistics and distribution providers, and facilities management.

We work with a diverse and geographically distributed supplier base. We recognise that complex, multi-tier global supply chains can limit transparency, particularly beyond direct suppliers, and may increase exposure to modern slavery risks in certain regions or sectors.

3. Policies and Governance

During the reporting period, Surgical Science established or strengthened a number of policies our approach to modern slavery and human rights, including:

- Modern Slavery and Human Rights Policy – our overarching policy setting out our commitments and expectations in relation to modern slavery, forced labour, child labour, and human rights across our operations and supply chains.
- Code of Conduct – which includes our commitments to fair working terms, non-discrimination, a healthy and safe workplace, and the prohibition of child labour and forced labour.
- Anti-Corruption and Bribery Policy – which supports ethical business conduct and reduces the risk of corrupt practices that can facilitate or be linked to exploitation.
- Supplier Code of Conduct – which sets out the minimum standards we expect our suppliers to uphold, including the prohibition of forced labour, child labour and human trafficking, and requirements around fair wages, working hours, and health and safety.
- Whistleblowing Policy – which provides confidential channels for employees and external parties to raise concerns, including in relation to suspected modern slavery, without fear of retaliation.

These policies are available to all employees and, where relevant, to suppliers and business partners.

4. Due Diligence

As this was our first reporting year, our activities focused on establishing the foundations of a proportionate, risk based due diligence approach.

During the reporting period, we:

- Conducted an initial high-level review of potential modern slavery risk areas in our operations and supply chains
- Developed and adopted a Group wide Modern Slavery and Human Rights Policy and Supplier Code of Conduct
- Began reviewing procurement practices and supplier engagement processes to improve transparency and oversight

We recognise that effective due diligence is iterative. Actions initiated following this reporting period are intended to strengthen our ability to identify, assess, and respond to risk over time.

5. Risk Assessment and Management

We have conducted an initial assessment of the modern slavery risks relevant to our business.

The nature of our core operations – a medical technology company with a highly skilled workforce – means that the risk of modern slavery in our direct operations is considered to be low.

However, we recognise that certain supply chain activities may present higher inherent risk, including:

- Historical use of a very large number of suppliers created limited visibility into the lower tiers of the supply chain. Certain sourcing practises involve goods that may pass through

multiple intermediaries, some of which may operate in regions or sectors with higher exposure to forced labour or other labour rights abuses.

- Some electronic components sourced through global supply chains may originate from regions with weaker labour protections, where the risk of exploitation is recognised to be higher.

The supplier consolidation programme described in Section 4 is the primary action that will be taken in 2026 to address these risks. By significantly reducing the number of supplier relationships we are improving our ability to know our supply chain and to set and monitor standards.

Improving supply chain visibility and strengthening supplier engagement are therefore key focus areas of our ongoing risk management approach.

6. Training and Awareness

Our Code of Conduct, which is provided to all employees, includes commitments relating to forced labour, child labour, and fair working terms.

As our approach matures, we intend to develop more targeted awareness and training activities for employees whose roles involve higher exposure to modern slavery risk, such as procurement, supply chain management, and human resources.

7. Monitoring and effectiveness

As a foundation year, we do not yet have a comprehensive set of performance metrics for measuring effectiveness. We intend to monitor progress over time using available indicators, such as:

- Employee awareness and training coverage
- Supplier engagement and acknowledgement of standards
- Concerns raised through whistleblowing or other reporting channels

During the reporting period, no instances or allegations of modern slavery were identified in our operations or supply chains. We acknowledge, however, that limited reporting may reflect the early stage of our systems and monitoring capabilities, and we do not interpret this as an absence of risk.

8. Looking ahead

In the next reporting period, we intend to continue strengthening our approach by:

Further embedding our Supplier Code of Conduct across active suppliers

Developing a more structured, risk-based approach to supplier assessment and monitoring

Enhancing supply chain transparency where feasible

Delivering targeted awareness activities for relevant employee groups

Reviewing and refining policies and processes in line with evolving best practice and regulatory expectations

We are committed to continuous improvement and to reporting transparently on progress in future statements.

9. Approval

This statement was approved by the Board of Directors of Surgical Science on 2026-05-21 and is signed by a director in accordance with Section 54(6) of the Modern Slavery Act 2015.

Signed on behalf of the Surgical Science Board of Directors:



Linus Bergqvist

Chief Operating Officer

2026-05-21